Catalyst Biosciences Price to Book Ratio 2006-2021 | CBIO

Historical price to book ratio values for Catalyst Biosciences (CBIO) over the last 10 years. The current price to book ratio for Catalyst Biosciences as of October 22, 2021 is 1.28.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Catalyst Biosciences Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 3.47 1.28
2021-06-30 4.33 $2.72 1.59
2021-03-31 5.04 $3.32 1.52
2020-12-31 6.31 $3.44 1.83
2020-09-30 4.30 $4.26 1.01
2020-06-30 5.87 $4.94 1.19
2020-03-31 4.37 $5.60 0.78
2019-12-31 6.81 $5.68 1.20
2019-09-30 4.91 $6.76 0.73
2019-06-30 7.37 $7.75 0.95
2019-03-31 8.11 $8.84 0.92
2018-12-31 7.89 $10.03 0.79
2018-09-30 10.78 $10.88 0.99
2018-06-30 11.67 $11.47 1.02
2018-03-31 25.80 $11.97 2.16
2017-12-31 13.64 $5.06 2.70
2017-09-30 5.06 $5.77 0.88
2017-06-30 4.65 $7.04 0.66
2017-03-31 9.43 $13.84 0.68
2016-12-31 9.75 $20.04 0.49
2016-09-30 18.15 $24.62 0.74
2016-06-30 22.80 $30.60 0.75
2016-03-31 25.20 $36.71 0.69
2015-12-31 46.95 $41.24 1.14
2015-09-30 69.90 $47.57 1.47
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.109B $0.021B
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76